TY - JOUR AU - Beatson, G. T. PY - 1896 DA - 1896// TI - On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment, with illustrative cases JO - Lancet VL - 148 UR - https://doi.org/10.1016/S0140-6736(01)72384-7 DO - 10.1016/S0140-6736(01)72384-7 ID - Beatson1896 ER - TY - STD TI - Rocca WA, Grossardt BR, de Andrade M, Malkasian GD, Melton 3rd LJ. Survival patterns after oophorectomy in premenopausal women: a population-based cohort study. Lancet Oncol. 2006;7:821–8. 2006. ID - ref2 ER - TY - JOUR AU - Vogel, V. G. PY - 2015 DA - 2015// TI - Ongoing data from the breast cancer prevention trials: opportunity for breast cancer risk reduction JO - BMC Med VL - 13 UR - https://doi.org/10.1186/s12916-015-0300-0 DO - 10.1186/s12916-015-0300-0 ID - Vogel2015 ER - TY - JOUR AU - Cuzick, J. AU - Sestak, I. AU - Cawthorn, S. AU - Hamed, H. AU - Holli, K. AU - Howell, A. PY - 2015 DA - 2015// TI - Tamoxifen for prevention of breast cancer: extended longterm follow-up of the IBIS-I breast cancer prevention trial JO - Lancet Oncol VL - 16 UR - https://doi.org/10.1016/S1470-2045(14)71171-4 DO - 10.1016/S1470-2045(14)71171-4 ID - Cuzick2015 ER - TY - JOUR AU - Waters, E. A. AU - McNeel, T. S. AU - Stevens, W. M. AU - Freedman, A. N. PY - 2012 DA - 2012// TI - Use of tamoxifen and raloxifene for breast cancer chemoprevention in 2010 JO - Breast Cancer Res Treat VL - 134 UR - https://doi.org/10.1007/s10549-012-2089-2 DO - 10.1007/s10549-012-2089-2 ID - Waters2012 ER - TY - STD TI - Early Breast Cancer Trialists’ Collaborative Group. Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet 2015; published online 23 July. http://www.ncbi.nlm.nih.gov/pubmed/?term=Aromatase+inhibitors+versus+tamoxifen+in+early+breast+cancer%3A+patient-level+metaanalysis+of+the+randomised+trials. (15)61074-1. UR - http://www.ncbi.nlm.nih.gov/pubmed/?term=Aromatase+inhibitors+versus+tamoxifen+in+early+breast+cancer%3A+patient-level+metaanalysis+of+the+randomised+trials ID - ref6 ER - TY - STD TI - Early Breast Cancer Trialists Collaborative Group (EBCTCG). Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet. 2011;378:771–84. ID - ref7 ER - TY - JOUR AU - Kim, C. AU - Tang, G. AU - Pogue-Geile, K. L. AU - Costantino, J. P. AU - Baehner, F. L. AU - Baker, J. PY - 2011 DA - 2011// TI - Estrogen receptor (ESR1) mRNA expression and benefit from tamoxifen in the treatment and prevention of estrogen receptor-positive breast cancer JO - J Clin Oncol VL - 29 UR - https://doi.org/10.1200/JCO.2010.32.9615 DO - 10.1200/JCO.2010.32.9615 ID - Kim2011 ER - TY - JOUR AU - Artigalás, O. AU - Vanni, T. AU - Hutz, M. H. AU - Ashton-Prolla, P. AU - Schwartz, I. V. PY - 2015 DA - 2015// TI - Influence of CYP19A1 polymorphisms on the treatment of breast cancer with aromatase inhibitors: a systematic review and meta-analysis JO - BMC Med VL - 13 UR - https://doi.org/10.1186/s12916-015-0373-9 DO - 10.1186/s12916-015-0373-9 ID - Artigalás2015 ER - TY - JOUR AU - Humphries, M. P. AU - Jordan, V. C. AU - Speirs, V. PY - 2015 DA - 2015// TI - Obesity and male breast cancer: provocative parallels? JO - BMC Med VL - 13 UR - https://doi.org/10.1186/s12916-015-0380-x DO - 10.1186/s12916-015-0380-x ID - Humphries2015 ER - TY - JOUR AU - Dunning, A. M. AU - Dowsett, M. AU - Healey, C. S. AU - Tee, L. AU - Luben, R. N. AU - Folkerd, E. PY - 2004 DA - 2004// TI - Polymorphisms associated with circulating sex hormone levels in postmenopausal women JO - J Natl Cancer Inst VL - 96 UR - https://doi.org/10.1093/jnci/djh167 DO - 10.1093/jnci/djh167 ID - Dunning2004 ER - TY - JOUR AU - Low, Y. L. AU - Li, Y. AU - Humphreys, K. AU - Thalamuthu, A. AU - Yi, L. AU - Darabi, H. PY - 2010 DA - 2010// TI - Multi-variant pathway association analysis reveals the importance of genetic determinants of estrogen metabolism in breast and endometrial cancer susceptibility JO - PLoS Genet VL - 6 UR - https://doi.org/10.1371/journal.pgen.1001012 DO - 10.1371/journal.pgen.1001012 ID - Low2010 ER - TY - JOUR AU - Wang, L. AU - Ellsworth, K. A. AU - Moon, I. AU - Pelleymounter, L. L. AU - Eckloff, B. W. AU - Martin, Y. N. PY - 2010 DA - 2010// TI - Functional genetic polymorphisms in the aromatase gene CYP19 vary the response of breast cancer patients to neoadjuvant therapy with aromatase inhibitors JO - Cancer Res VL - 70 UR - https://doi.org/10.1158/0008-5472.CAN-09-3224 DO - 10.1158/0008-5472.CAN-09-3224 ID - Wang2010 ER - TY - JOUR AU - Migliaccio, I. AU - Malorni, L. AU - Hart, C. D. AU - Guarducci, C. AU - Leo, A. PY - 2015 DA - 2015// TI - Endocrine therapy considerations in postmenopausal patients with hormone receptor positive, human epidermal growth factor receptor type 2 negative advanced breast cancers JO - BMC Med VL - 13 UR - https://doi.org/10.1186/s12916-015-0280-0 DO - 10.1186/s12916-015-0280-0 ID - Migliaccio2015 ER - TY - JOUR AU - Yamamoto-Ibusuki, M. AU - Arnedos, M. AU - André, F. PY - 2015 DA - 2015// TI - Targeted therapies for ER+/HER2- metastatic breast cancer JO - BMC Med VL - 13 UR - https://doi.org/10.1186/s12916-015-0369-5 DO - 10.1186/s12916-015-0369-5 ID - Yamamoto-Ibusuki2015 ER - TY - JOUR AU - Baselga, J. AU - Campone, M. AU - Piccart, M. AU - Burris, H. A. AU - Rugo, H. S. AU - Sahmoud, T. PY - 2012 DA - 2012// TI - Everolimus in postmenopausal hormone receptor-positive advanced breast cancer JO - N Engl J Med VL - 366 UR - https://doi.org/10.1056/NEJMoa1109653 DO - 10.1056/NEJMoa1109653 ID - Baselga2012 ER - TY - JOUR AU - Piccart, M. AU - Hortobagyi, G. N. AU - Campone, M. AU - Pritchard, K. I. AU - Lebrun, F. AU - Ito, Y. PY - 2014 DA - 2014// TI - Everolimus plus exemestane for hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2 JO - Ann Oncol VL - 25 UR - https://doi.org/10.1093/annonc/mdu456 DO - 10.1093/annonc/mdu456 ID - Piccart2014 ER - TY - JOUR AU - Finn, R. S. AU - Crown, J. P. AU - Lang, I. AU - Boer, K. AU - Bondarenko, I. M. AU - Kulyk, S. O. PY - 2015 DA - 2015// TI - The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study JO - Lancet Oncol VL - 16 UR - https://doi.org/10.1016/S1470-2045(14)71159-3 DO - 10.1016/S1470-2045(14)71159-3 ID - Finn2015 ER - TY - JOUR AU - Turner, N. C. AU - Ro, J. AU - Andre, F. AU - Loi, S. AU - Verma, S. AU - Iwata, H. PY - 2015 DA - 2015// TI - Palbociclib in hormone-receptor–positive advanced breast cancer JO - New Engl J Med VL - 373 UR - https://doi.org/10.1056/NEJMoa1505270 DO - 10.1056/NEJMoa1505270 ID - Turner2015 ER - TY - JOUR AU - Ligibel, J. A. AU - Alfano, C. M. AU - Courneya, K. S. AU - Demark-Wahnefried, W. AU - Burger, R. A. AU - Chlebowski, R. T. PY - 2014 DA - 2014// TI - American Society of Clinical Oncology position statement on obesity and cancer JO - J Clin Oncol VL - 32 UR - https://doi.org/10.1200/JCO.2014.58.4680 DO - 10.1200/JCO.2014.58.4680 ID - Ligibel2014 ER - TY - JOUR AU - Waart, H. AU - Stuiver, M. M. AU - Harten, W. H. AU - Geleijn, E. AU - Kieffer, J. M. AU - Buffart, L. M. PY - 2015 DA - 2015// TI - Effect of low-intensity physical activity and moderate- to high-intensity physical exercise during adjuvant chemotherapy on physical fitness, fatigue, and chemotherapy completion rates: results of the PACES randomized clinical trial JO - J Clin Oncol VL - 33 UR - https://doi.org/10.1200/JCO.2014.59.1081 DO - 10.1200/JCO.2014.59.1081 ID - Waart2015 ER - TY - JOUR AU - Travier, N. AU - Velthuis, M. J. AU - Steins Bisschop, C. N. AU - Buijs, B. AU - Monninkhof, E. M. AU - Backx, F. PY - 2015 DA - 2015// TI - Effects of an 18-week exercise programme started early during breast cancer treatment: a randomised controlled trial JO - BMC Med VL - 13 UR - https://doi.org/10.1186/s12916-015-0362-z DO - 10.1186/s12916-015-0362-z ID - Travier2015 ER - TY - JOUR AU - Kim, M. AU - Agarwal, S. AU - Tripathy, D. PY - 2014 DA - 2014// TI - Updates on the treatment of human epidermal growth factor receptor type 2-positive breast cancer JO - Curr Opin Obstet Gynecol VL - 26 UR - https://doi.org/10.1097/GCO.0000000000000043 DO - 10.1097/GCO.0000000000000043 ID - Kim2014 ER - TY - JOUR AU - Rexer, B. N. AU - Arteaga, C. L. PY - 2012 DA - 2012// TI - Intrinsic and acquired resistance to HER2-targeted therapies in HER2 gene-amplified breast cancer: mechanisms and clinical implications JO - Crit Rev Oncog VL - 17 UR - https://doi.org/10.1615/CritRevOncog.v17.i1.20 DO - 10.1615/CritRevOncog.v17.i1.20 ID - Rexer2012 ER - TY - JOUR AU - Sonnenblick, A. AU - Brohée, S. AU - Fumagalli, D. AU - Vincent, D. AU - Venet, D. AU - Ignatiadis, M. PY - 2015 DA - 2015// TI - Constitutive phosphorylated STAT3-associated gene signature is predictive for trastuzumab resistance in primary HER2-positive breast cancer JO - BMC Med VL - 13 UR - https://doi.org/10.1186/s12916-015-0416-2 DO - 10.1186/s12916-015-0416-2 ID - Sonnenblick2015 ER -